# Gilead Sciences

> Gilead Sciences develops and sells prescription medicines for HIV, liver diseases, cancer and other serious conditions. Its antiviral expertise has produced single-tablet HIV regimens, hepatitis C treatments with high cure rates and twice-yearly HIV prevention; acquisitions have expanded its cell therapy and oncology businesses.

- **Founded:** 1987
- **Headquarters:** Foster City, United States
- **Founders:** Michael L. Riordan (Founder and founding chief executive officer)
- **Products:** Atripla, Sovaldi, Biktarvy, Descovy, Yescarta
- **Notable:** Atripla received FDA approval in July 2006 as the first once-daily single-tablet HIV regimen., Sovaldi received FDA approval in December 2013, supporting short-course hepatitis C regimens with high cure rates., Yeztugo received U.S. approval in June 2025 as the first twice-yearly HIV PrEP option.

## Products & services

- **Atripla** — Single-tablet HIV regimen developed through a joint venture with Bristol-Myers Squibb; first U.S. approval in 2006.
- **Sovaldi** — Sofosbuvir, approved in combination regimens for chronic hepatitis C; enabled shortened treatment with high cure rates.
- **Biktarvy** — Once-daily, single-tablet HIV treatment combining bictegravir, emtricitabine and tenofovir alafenamide; first U.S. approval in 2018.
- **Descovy** — Emtricitabine/tenofovir alafenamide used in HIV treatment combinations and, for eligible populations, oral HIV PrEP; U.S. PrEP approval in 2019.
- **Yescarta** — Kite CAR T-cell therapy for specified blood cancers; first FDA approval in 2017.
- **Tecartus** — Kite CAR T-cell therapy for specified blood cancers; first FDA approval in 2020.
- **Trodelvy** — Antibody-drug conjugate used for specified breast cancers; acquired with Immunomedics in 2020. Its U.S. urothelial cancer indication was withdrawn in 2024.
- **Veklury** — Remdesivir, an intravenous antiviral for eligible patients with COVID-19.
- **Livdelzi** — Seladelpar for eligible adults with primary biliary cholangitis; received FDA accelerated approval in August 2024.
- **Yeztugo** — Lenacapavir for twice-yearly HIV pre-exposure prophylaxis in eligible adults and adolescents weighing at least 35 kg; requires HIV testing and initial oral dosing.
- **Bixlenvo** — Daily bictegravir/lenacapavir tablet approved in the U.S. in August 2026 for eligible virologically suppressed adults with HIV, including those switching from complex regimens.

## Achievements

- Atripla received FDA approval in July 2006 as the first once-daily single-tablet HIV regimen.
- Sovaldi received FDA approval in December 2013, supporting short-course hepatitis C regimens with high cure rates.
- Yeztugo received U.S. approval in June 2025 as the first twice-yearly HIV PrEP option.
- Biktarvy generated approximately $14.3 billion in 2025 sales.

## Latest updates

- **2026-08** — Second-quarter results reported $5.693 billion in HIV product sales, up 12%, and $417 million in cell therapy sales, down 14% from the prior-year quarter.
- **2026-08** — FDA approved Bixlenvo on August 27 for eligible virologically suppressed adults with HIV.
- **2026-09** — Gilead expanded its six lenacapavir generic licenses to include the investigational once-yearly prevention formulation; no regulatory approval for that formulation was announced.
- **2026-10** — Gilead announced 28 presentations for IDWeek, October 21-24, spanning HIV treatment, prevention and investigational GS-1179 for recurrent genital herpes.

## Links

- Website: https://www.gilead.com
- LinkedIn: https://www.linkedin.com/company/gilead-sciences/
- Twitter/X: https://twitter.com/GileadSciences
- YouTube: https://www.youtube.com/channel/UCNSt7PtsfNGbezR9hmvRI1w
- Instagram: https://www.instagram.com/gileadsciences/
- Facebook: https://www.facebook.com/GileadSciences

---

Profile page: https://yespress.io/gilead-sciences
Published by YesPress — https://yespress.io
Last updated: 2026-10-22